Multibagger Insights
Subscribe
Sign in
Home
Notes
Deep Dives
Shallow Theses
Lessons
Archive
Leaderboard
About
Which Software Stock Survives the AI Transition?
ServiceNow vs. Salesforce vs. Adobe vs. GitLab: My Software Stock Pick for 2026
Jan 12
•
The T-shaped Investor
7
4
PricedIn: A Quick Valuation Browser Extension
Reverse Discounted Cash Flow: Working Backwards to Find Value
Jan 1
•
The T-shaped Investor
4
2
3
Quick Thoughts On Harrow Inc
VEVYE and IHEEZO Today, Biosimilars and MELT-300 Tomorrow, and My Valuation for 2027.
Dec 4, 2025
•
The T-shaped Investor
7
3
Eton Pharmaceuticals: A Growth Story in Ultra-rare Disease Niche
How Acquisitions, Pipeline Assets, and Margin Gains Fuel Eton’s Upside.
Nov 18, 2025
•
The T-shaped Investor
3
4
Doubling Down? Why Duolingo’s Upside Warrants Caution and Conviction
Weighing long-term upside against platform risks as Duolingo hits its most compelling valuation yet.
Oct 31, 2025
•
The T-shaped Investor
4
2
Most Popular
View all
Why I Remain Bullish about Harrow Inc
Oct 5, 2025
•
The T-shaped Investor
13
2
Quick Thoughts On Harrow Inc
Dec 4, 2025
•
The T-shaped Investor
7
3
Zeta Global: Data, Diversification, and Dilemmas
Sep 8, 2025
•
The T-shaped Investor
19
2
5
ASML's Asymmetric Upside
Jul 23, 2025
•
The T-shaped Investor
18
3
8
Latest
Top
Discussions
Why I Remain Bullish about Harrow Inc
Key reasons for my optimism: product development, affordability, and future pipeline.
Oct 5, 2025
•
The T-shaped Investor
13
2
Zeta Global: Data, Diversification, and Dilemmas
A Balanced Look at Zeta’s Strengths, Valuation, and Lingering Concerns
Sep 8, 2025
•
The T-shaped Investor
19
2
5
PROCEPT BioRobotics
A High-Growth Leader in BPH Treatment Facing Headwinds on the Road to Profitability
Sep 2, 2025
•
The T-shaped Investor
8
2
4
Harrow Inc: Asymmetric Upside with Real Risks
Scaling branded products, Expanding into Retinal Biosimilars, and Reshaping U.S. Eyecare
Aug 19, 2025
•
The T-shaped Investor
11
1
5
FICO’s Dominance Tested: High Rewards, High Risk
Unpacking FICO’s Market Leadership, Growth Opportunities, and the High-Stakes Risk of Customer and Competitive Disruption
Aug 3, 2025
•
The T-shaped Investor
12
3
4
Figma: The Collaborative Design Powerhouse
A category-defining design platform with rapid growth, sticky economics, and a rich IPO valuation testing investor conviction.
Jul 29, 2025
•
The T-shaped Investor
9
6
ASML's Asymmetric Upside
A Deep Dive into Management Guidance, Customer Capex, and Bull vs. Bear Valuation Paths
Jul 23, 2025
•
The T-shaped Investor
18
3
8
The 4% Rule Still Works — If You Outperform Just a Little
Backtesting the 4% Rule: Outperformance vs. Lower Spending in Retirement
Jul 17, 2025
•
The T-shaped Investor
5
4
Not All Growth Is Equal: The Anatomy of a 10x Valuation
Why some companies command premium multiples—and how to spot them before everyone else does
Jul 12, 2025
•
The T-shaped Investor
6
7
See all
Multibagger Insights
Broad research. Deep conviction. A T-shaped approach to hunting multibaggers. I share the rigorous 'Buy or Pass' theses behind my personal portfolio.
Subscribe
Recommendations
View all 25
The Pragmatic Optimist
Amrita Roy
Optiva
Matej Pretković
ASYMMETRIC EDGE
Asymmetric Edge
School of Investing
School of Investing
AI Supremacy
Michael Spencer
Multibagger Insights
Subscribe
About
Archive
Recommendations
Sitemap
This site requires JavaScript to run correctly. Please
turn on JavaScript
or unblock scripts